Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis
Jasmohan S. Bajaj, … , Masoumeh Sikaroodi, Patrick M. Gillevet
Jasmohan S. Bajaj, … , Masoumeh Sikaroodi, Patrick M. Gillevet
Published March 8, 2018
Citation Information: JCI Insight. 2018;3(5):e98019. https://doi.org/10.1172/jci.insight.98019.
View: Text | PDF
Clinical Medicine Hepatology

Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis

  • Text
  • PDF
Abstract

BACKGROUND. Cirrhosis is associated with gut microbial changes, but current 16S rDNA techniques sequence both dead and live bacteria. We aimed to determine the rRNA content compared with DNA from the same stool sample to evaluate cirrhosis progression and predict hospitalizations. METHODS. Cirrhotics and controls provided stool for RNA and DNA analysis. Comparisons were made between cirrhotics/controls and within cirrhosis (compensated/decompensated, infected/uninfected, renal dysfunction/not, rifaximin use/not) with respect to DNA and RNA bacterial content using linear discriminant analysis. A separate group was treated with omeprazole for 14 days with longitudinal microbiota evaluation. Patients were followed for 90 days for hospitalizations. Multivariable models for hospitalizations with clinical data with and without DNA and RNA microbial data were created. RESULTS. Twenty-six controls and 154 cirrhotics (54 infected, 62 decompensated, 20 renal dysfunction, 18 rifaximin) were included. RNA and DNA analysis showed differing potentially pathogenic taxa but similar autochthonous taxa composition. Thirty subjects underwent the omeprazole study, which demonstrated differences between RNA and DNA changes. Thirty-six patients were hospitalized within 90 days. In the RNA model, MELD score and Enterococcus were independently predictive of hospitalizations, while in the DNA model MELD was predictive and Roseburia protective. In both models, adding microbiota significantly added to the MELD score in predicting hospitalizations. CONCLUSION. DNA and RNA analysis of the same stool sample demonstrated differing microbiota composition, which independently predicts the hospitalization risk in cirrhosis. RNA and DNA content of gut microbiota in cirrhosis are modulated differentially with disease severity, infections, and omeprazole use. TRIAL REGISTRATION. NCT01458990. FUNDING. VA Merit I0CX001076.

Authors

Jasmohan S. Bajaj, Leroy R. Thacker, Andrew Fagan, Melanie B. White, Edith A. Gavis, Phillip B. Hylemon, Robert Brown, Chathur Acharya, Douglas M. Heuman, Michael Fuchs, Swati Dalmet, Masoumeh Sikaroodi, Patrick M. Gillevet

×

Figure 6

Comparison of controls and cirrhotic patients before/after 14 days of omeprazole.

Options: View larger image (or click on image) Download as PowerPoint
Comparison of controls and cirrhotic patients before/after 14 days of om...
Healthy controls and compensated cirrhotic patients were administered 40 mg/day of omeprazole for 14 days. Stool microbiota were analyzed at baseline and after 14 days using Wilcoxon’s signed rank-sum test, focusing on relative abundance of oral-origin families Streptococcaceae and Veillonellaceae. (A) DNA comparison. (B) RNA comparison. Data shown as median and 95% CI. *P < 0.05, **P < 0.01. Ctrl, control; Cirr, compensated cirrhosis; Pre, before omeprazole; Post, after 14 days of 40 mg omeprazole daily.
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts